Will Booking Holdings Stock Split?
Booking Holdings, the travel and technology company that owns brands…
Buy
59
MDXH Quote, Financials, Valuation and Earnings
Last price:
$2.3300
Seasonality move
:
-1.31%
Day range:
$2.3100 - $2.3700
52-week range:
$1.5500 - $4.6400
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.89x
P/B ratio:
6.76x
Volume:
67.7K
Avg. volume:
147K
1-year change:
-41.85%
Market cap:
$114.8M
Revenue:
$70.2M
EPS (TTM):
-$1.52
Analysts' Opinion
-
Consensus RatingMDxHealth SA has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.1750, MDxHealth SA has an estimated upside of 160.35% from its current price of $2.3200.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.7000 representing 100% downside risk from its current price of $2.3200.
Fair Value
-
According to the consensus of 4 analysts, MDxHealth SA has 160.35% upside to fair value with a price target of $7.1750 per share.
MDXH vs. S&P 500
-
Over the past 5 trading days, MDxHealth SA has overperformed the S&P 500 by 4.07% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
MDxHealth SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MDxHealth SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter MDxHealth SA reported revenues of $23.3M.
Earnings Growth
-
MDxHealth SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter MDxHealth SA reported earnings per share of -$0.40.
Enterprise value:
116.9M
EV / Invested capital:
--
Price / LTM sales:
0.89x
EV / EBIT:
--
EV / Revenue:
1.38x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-4.54x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$52.3M
Return On Assets:
-31.08%
Net Income Margin (TTM):
-49.52%
Return On Equity:
-650.14%
Return On Invested Capital:
-85.88%
Operating Margin:
-26.13%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $30.2M | $63.7M | $84.7M | $19.4M | $23.3M | |
| Gross Profit | $14.8M | $38.5M | $52.3M | $12.6M | $14.3M | |
| Operating Income | -$36.4M | -$30.5M | -$25.8M | -$4.6M | -$6.1M | |
| EBITDA | -$33M | -$28.7M | -$32.1M | -$2.1M | -$3.7M | |
| Diluted EPS | -$2.58 | -$2.06 | -$1.52 | -$0.37 | -$0.40 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $40.9M | $45.6M | $70.2M | |
| Total Assets | -- | -- | $122.6M | $135.7M | $157.4M | |
| Current Liabilities | -- | -- | $19.3M | $18.8M | $45.5M | |
| Total Liabilities | -- | -- | $101.1M | $117.9M | $140.4M | |
| Total Equity | -- | -- | $21.5M | $17.8M | $17M | |
| Total Debt | -- | -- | $35.3M | $36M | $51.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$23.8M | -$22.8M | -$4.3M | -$5.6M | |
| Cash From Investing | -- | -$6.3M | -$2.1M | -$439K | -$13K | |
| Cash From Financing | -- | $34.5M | $41.4M | -$2.3M | $33.6M | |
| Free Cash Flow | -- | -$30.6M | -$25.8M | -$5.1M | -$5.8M | |
MDXH
Sector
Market Cap
$114.8M
$49.2M
Price % of 52-Week High
50%
48.57%
Dividend Yield
0%
0%
Shareholder Yield
-40.99%
-0.74%
1-Year Price Total Return
-41.86%
-30.94%
Beta (5-Year)
-384,676.085
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$2.2738
200-day SMA
Sell
Level
$2.4790
Bollinger Bands (100)
Buy
Level
1.88 - 2.7
Chaikin Money Flow
Sell
Level
-1.9M
20-day SMA
Buy
Level
$2.2670
Relative Strength Index (RSI14)
Buy
Level
57.3686
ADX Line
Buy
Level
23.8475
Williams %R
Neutral
Level
-51.5152
50-day SMA
Buy
Level
$2.0652
MACD (12, 26)
Buy
Level
0.0728
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Sell
Level
-658.5K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.3063)
Sell
CA Score
(Annual)
Level (-3.5959)
Buy
Beneish M-Score
(Annual)
Level (-2.8713)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (5.3952)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
Stock Forecast FAQ
In the current month, MDXH has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MDXH average analyst price target in the past 3 months is $7.1750.
-
Where Will MDxHealth SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that MDxHealth SA share price will rise to $7.1750 per share over the next 12 months.
-
What Do Analysts Say About MDxHealth SA?
Analysts are divided on their view about MDxHealth SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MDxHealth SA is a Sell and believe this share price will drop from its current level to $5.7000.
-
What Is MDxHealth SA's Price Target?
The price target for MDxHealth SA over the next 1-year time period is forecast to be $7.1750 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MDXH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MDxHealth SA is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MDXH?
You can purchase shares of MDxHealth SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MDxHealth SA shares.
-
What Is The MDxHealth SA Share Price Today?
MDxHealth SA was last trading at $2.3300 per share. This represents the most recent stock quote for MDxHealth SA. Yesterday, MDxHealth SA closed at $2.3200 per share.
-
How To Buy MDxHealth SA Stock Online?
In order to purchase MDxHealth SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Buy Domino’s Pizza Stock?
When you think of growth stocks, you probably imagine technology…
What Companies Are In The VanEck Semiconductor ETF?
There’s a lot to love about the VanEck Semiconductor ETF,…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
39
DOGZ alert for Jan 4
Dogness (International) [DOGZ] is down 20.52% over the past day.
Buy
66
DMRC alert for Jan 4
Digimarc [DMRC] is up 16.19% over the past day.
Sell
39
MSTR alert for Jan 4
MicroStrategy [MSTR] is up 13.33% over the past day.
